In the Brazilian candidaemia study, the 30-day mortality of patients treated with deoxycholate amphotericin B (n = 131) and fluconazole (n = 102) was 61% and 55%, respectively, and in the Latin American study, the 30-day mortality of patients receiving deoxycholate amphotericin B (n = 87) and fluconazole (n = 286) was 51% and 42% (unpublished data). Therefore, the 43.1% 30-day

mortality of patients treated with anidulafungin in this study is comparable to the data from the more recent study in the region. Favourable responses have been achieved this website in other clinical studies of treatment of candidaemia where a triazole was used as step-down therapy following treatment with IV anidulafungin.[20, 21] In this study, only 14 of 44 (31.8%) patients in the MITT population were able to step-down from IV anidulafungin to oral voriconazole. These patients had relatively low APACHE II scores and were less likely to have solid tumours or prior abdominal surgery, thus suggesting that they represented a less sick population. Accordingly, the global response rate was significantly higher in this group LDK378 datasheet of patients and the 30-day mortality was lower than for patients who were not able to step-down (7.1% vs. 60% respectively). Although limited by

a small sample size, this open-label study suggests that anidulafungin is an acceptable alternative to fluconazole for the treatment of C/IC in Latin American patients. Likewise, while a relatively small proportion of patients were able to step-down to oral therapy, the study provided preliminary insights into a subgroup of patients for whom this treatment strategy might be appropriate. Parameters that can aid early identification of this subgroup of patients may help to tailor the treatment of candidaemia, with important economic implications for the overall management of candidaemia. The authors thank the Protein kinase N1 A8851015 investigators and study team. This study was sponsored by Pfizer Inc. Editorial support was provided

by Dean Clarke and Anne Marie Reid of Complete Medical Communications and was funded by Pfizer Inc. MN has acted as a speaker and consultant, and received research grants from Astellas, Merck and Pfizer. ALC has received grant support for educational programmes from Astellas, Merck, Pfizer and United Medical. MP and SS were employees of Pfizer Inc at the time of the study. MM has acted as a speaker for Pfizer. HS and PA are full-time employees of Pfizer Inc. “
“This study evaluated the in vitro interaction between ciprofloxacin (CIP) and classical antifungals against Histoplasma capsulatum var. capsulatum in mycelial (n = 16) and yeast-like forms (n = 9) and Coccidioides posadasii in mycelial form (n = 16). This research was conducted through broth microdilution and macrodilution, according to Clinical Laboratory Standards Institute. Inocula were prepared to obtain from 0.5 × 103 to 2.5 × 104 cfu ml−1 for H. capsulatum and from 103 to 5 × 103 cfu ml−1 for C. posadasii.